WASHINGTON (AP) — Healthpoint Ltd. and DFB Pharmaceuticals will pay up to $48 million to settle allegations that Healthpoint marketed a prescription skin ointment without approval from federal regulators.
The Justice Department said Healthpoint caused false claims for reimbursement to be submitted to Medicare and Medicaid for Xenaderm, which is used for treating nursing home patients' bed sores. Fort Worth, Texas-based Healthpoint is one of DFB's operating companies.
The government alleged that Healthpoint's business strategy was to market new prescription drugs modeled after products that were available before October 1962 in order to avoid the time, effort and expense of obtaining approval from the Food and Drug Administration. Products containing Xenaderm's principal active ingredient were on the market before 1962, but the FDA determined the ingredient was less-than-effective for its intended use.
Wyo., ND Governors To EPA: Hey, We Need More Time On Clean Power Plan Regulations Because You Totally ‘Blindsided’ Us | Matt Vespa
House Democrats Will Try To Dissolve Select Committee On Benghazi Tonight UPDATE: Voted Down, Committee Remains | Matt Vespa
Homeowner Stops Three Robbers By Pleading For Mercy. Just Kidding. He Shot Them. - Bearing Arms - Guns Saving Lives, Texas
War Party Targets Putin and Assad | Human Events
Thomas Sowell - Charlatans and Sheep
Ted Cruz finds a question that the Sierra Club DARED not answer. | RedState
The truth about gun deaths: numbers and actual solutions
- MSNBC’s Chris Hayes: The Problem is the Constitution
Second data storage firm emerges with possible cloud backups of Hillary Clinton's emails - twitchy.com